Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.00 Average Price Target from Brokerages

Quince Therapeutics, Inc. (NASDAQ:QNCX) has been given a consensus rating of “Moderate Buy” by the seven research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $8.00.

Several research analysts recently commented on QNCX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Quince Therapeutics in a report on Monday, December 15th. D. Boral Capital raised their price objective on Quince Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, Zacks Research upgraded Quince Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th.

Institutional Investors Weigh In On Quince Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of QNCX. Bridgeway Capital Management LLC lifted its position in shares of Quince Therapeutics by 20.9% during the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock worth $212,000 after purchasing an additional 22,200 shares during the last quarter. XTX Topco Ltd acquired a new position in Quince Therapeutics in the second quarter worth $37,000. GSA Capital Partners LLP increased its stake in Quince Therapeutics by 158.0% during the third quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock valued at $142,000 after purchasing an additional 53,417 shares during the last quarter. Union Square Park Capital Management LLC raised its holdings in shares of Quince Therapeutics by 86.0% during the third quarter. Union Square Park Capital Management LLC now owns 224,746 shares of the company’s stock worth $366,000 after purchasing an additional 103,889 shares during the period. Finally, Rockefeller Capital Management L.P. acquired a new position in shares of Quince Therapeutics in the 2nd quarter valued at about $280,000. Institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Stock Performance

Shares of NASDAQ QNCX opened at $3.57 on Thursday. Quince Therapeutics has a 1 year low of $0.72 and a 1 year high of $4.55. The firm’s 50 day moving average price is $2.51 and its 200 day moving average price is $1.92. The firm has a market cap of $198.78 million, a P/E ratio of -2.95 and a beta of 1.03.

Quince Therapeutics (NASDAQ:QNCX) last released its earnings results on Wednesday, November 12th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.05). As a group, equities analysts predict that Quince Therapeutics will post -1.21 EPS for the current year.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.